Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

Xu, Xiaogang; Xiang-yang, FU; Xue, Feng; Huang, Qiao; Li, Daojun; Lu, Mengji

doi:10.1007/s00280-010-1450-6

Cited by 13 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies that focused on efficacy of erlotinib after gefitinib failure were excluded. The results are summarized in Supplementary Table 2 [11][12][13]27,28]. We found 5 studies with total 81 patients.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Retrospective study of erlotinib in patients with advanced squamous lung cancer

Tseng¹,

Yang²,

Chen³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

“…Several studies independently observed the objective responses of erlotinib in lung SCC patients [11][12][13]. However, the real efficacy of erlotinib in these patients remains unclear due to limited case numbers of these studies.…”

Section: Introductionmentioning

confidence: 96%

Retrospective study of erlotinib in patients with advanced squamous lung cancer

Tseng¹,

Yang²,

Chen³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

“…It emphasizes the importance of risk assessment of tumor progression in these patients, and CTCs are considered as the predictive biomarker for guiding cancer treatment strategies [25]. CTCs count was proved to predict the radiation therapy response of NSCLC patients [26].…”

Section: Discussionmentioning

confidence: 99%

Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review

et al. 2017

View full text Add to dashboard Cite

PurposeThe study aimed to monitor circulating tumor cells (CTCs) in early stage lung adenocarcinoma patients.ResultsCTCs were characterized and classified to epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs, as per epithelial-mesenchymal transition(EMT) biomarkers. CTCs could not be found in healthy controls. However, in cohort A, CTCs were found in 17 (17/18) cases. Detection rate of E-CTCs was lower (5/18) compared with M-CTC (10/18) or E&M-CTC (14/18). Highly abundant M-CTCs were prone to being in the tumors > 2 cm. In cohorts A and B, CTCs count increased significantly in all patients with tumor progression (7/7). Higher CTCs level or change range could be found postoperatively in the patients with tumor progression, as compared with patients with disease free survival (P < 0.01). Additionally, CTCs detected by CanPatrolTM could be validated by CytoploRare or Pep@MNPs.Materials and MethodsWe included four cohorts of patients and 20 healthy controls. In cohort A, CTCs were detected by a newly established approach, i.e., CanPatrolTM, prior to anesthesia and monitored after operation longitudinally. In cohort B, CTCs were not assessed prior to operation, but were longitudinally detected after operation. For validation, we detected FOLR(+)-CTCs by using CytoploRare and EPCAM(+)-CTCs by using Pep@MNPs prior to operation, in cohorts C and D, respectively.ConclusionCTCs can be detected in early stage lung adenocarcinoma, even in adenocarcinoma in situ, and CTCs detection can effectively monitor tumor progression. The distinguishing of biomarkers of highly invasive and aggressive CTCs warrants further robust study.

show abstract

“…Molecular targeted therapies have advanced most for younger patients with LUAD, who are mostly neversmokers. Recently, EGFR-TKI has emerged as an alternative treatment option for advanced NSCLC [7][8][9]. ese findings suggest that erlotinib monotherapy is an effective and well-tolerated treatment option for elderly Asian patients with advanced NSCLC [7].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, EGFR-TKI has emerged as an alternative treatment option for advanced NSCLC [7][8][9]. ese findings suggest that erlotinib monotherapy is an effective and well-tolerated treatment option for elderly Asian patients with advanced NSCLC [7]. Moreover, in patients suffering from advanced NSCLC, bevacizumab improved the overall survival when paclitaxel-carboplatin was added [10].…”

Section: Introductionmentioning

confidence: 99%

Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application

Shi

Sheng

Cheng

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality worldwide. Tumorigenesis involves a multistep process resulting from the interactions of genetic, epigenetic, and environmental factors. Genome-wide association studies and sequencing studies have identified many epigenetic alterations associated with the development of lung cancer. Epigenetic mechanisms, mainly including DNA methylation, histone modification, and noncoding RNAs (ncRNAs), are heritable and reversible modifications that are involved in some important biological processes and affect cancer hallmarks. We summarize the major epigenetic modifications in lung cancer, focusing on DNA methylation and ncRNAs, their roles in tumorigenesis, and their effects on key signaling pathways. In addition, we describe the clinical application of epigenetic biomarkers in the early diagnosis, prognosis prediction, and oncotherapy of lung cancer. Understanding the epigenetic regulation mechanism of lung cancer can provide a new explanation for tumorigenesis and a new target for the precise treatment of lung cancer.

show abstract

Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

Abstract: The results suggest that erlotinib monotherapy is an effective and well-tolerated treatment option for Asian elderly patients with advanced NSCLC.

Cited by 13 publications

References 16 publications

Retrospective study of erlotinib in patients with advanced squamous lung cancer

Retrospective study of erlotinib in patients with advanced squamous lung cancer

Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review

Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application

Contact Info

Product

Resources

About